Production (Stage)
Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.04% | 47.77% | 19.29% | 34.35% | 99.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.43% | -37.54% | -5.28% | 14.80% | 89.27% |
| Operating Income | -6.43% | 37.54% | 5.28% | -14.80% | -89.27% |
| Income Before Tax | -9.96% | 28.76% | -22.37% | 36.16% | -55.50% |
| Income Tax Expenses | -44.00% | -95.05% | -- | -- | -- |
| Earnings from Continuing Operations | -9.91% | 28.99% | -22.37% | 36.21% | -55.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -95.87% | -93.85% | -72.52% | -56.18% | 87.64% |
| Net Income | -11.91% | 26.58% | -25.88% | 35.94% | -55.13% |
| EBIT | -6.43% | 37.54% | 5.28% | -14.80% | -89.27% |
| EBITDA | -6.40% | -24.09% | 5.56% | -15.37% | -90.00% |
| EPS Basic | 1.34% | -15.70% | 9.84% | 60.43% | -16.82% |
| Normalized Basic EPS | 8.65% | 42.32% | 8.14% | 60.19% | -16.56% |
| EPS Diluted | 1.34% | -17.84% | 9.84% | 60.43% | -16.82% |
| Normalized Diluted EPS | 8.65% | 42.32% | 8.14% | 60.19% | -16.56% |
| Average Basic Shares Outstanding | 23.86% | 30.51% | 39.56% | 61.85% | 32.75% |
| Average Diluted Shares Outstanding | 23.86% | 30.51% | 39.56% | 61.85% | 32.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |